Vedanta Biosciences is pioneering a novel class of therapies designed to modulate pathways of interaction between the human microbiome and the host immune system. The first to rationally design a drug candidate based on consortia of human commensal bacteria, Vedanta has capabilities that enable discovery, development, and manufacturing of drugs based on live commensal microbes. Vedanta is advancing a pipeline of product candidates designed to treat autoimmune, inflammatory and infectious diseases, which have been developed using Vedanta\'s proprietary technology platform.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/23/19 | $16,600,000 | Series C-2 |
FC Capital Partners Investment Co. QUAD Investment Management Shinhan Capital-Yeollim Partners Shinhan Investment-Private Equity SV Investment Symbiosis | undisclosed |
| 07/21/21 | $68,000,000 | Series D |
Fosun Health Capital JSR Corporation Magnetar Capital  Pfizer Strategic Investments Group PureTech Health Rock Springs Capital Seventure Partners Shumway Capital Skyviews Life Science Symbiosis Verition Fund Management | undisclosed |
